GeoVax Labs, Inc. (GOVX) stock
GOVXNasdaqPharmaceutical PreparationsFiscal year ends December 31
$1.99−0.02 (-1.00%)
Close on Nov 18, 2026Market cap $14.66MP/E –Yield –
GeoVax Labs revenue
Revenue is the money a company takes in from selling its products and services, before any costs are deducted.
GeoVax Labs's revenue for the twelve months ending Jun 30, 2026 was $0, down 100.0% year over year. For fiscal 2025 it was $2.49M, down 37.1% from the year before. The highest annual figure on record is $3.95M in fiscal 2024.
Annual revenue
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.49M | -37.1% |
| FY2024 | Dec 31, 2024 | $3.95M | – |
| FY2023 | Dec 31, 2023 | $0 | -100.0% |
| FY2022 | Dec 31, 2022 | $81.53K | -78.9% |
| FY2021 | Dec 31, 2021 | $385.50K | -78.9% |
| FY2020 | Dec 31, 2020 | $1.82M | +55.1% |
| FY2019 | Dec 31, 2019 | $1.18M | +22.1% |
| FY2018 | Dec 31, 2018 | $963.20K | -10.4% |
| FY2017 | Dec 31, 2017 | $1.08M | +29.7% |
| FY2016 | Dec 31, 2016 | $828.92K | – |
Quarterly revenue
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $0 | -100.0% |
| Q1 FY2026 | Mar 31, 2026 | $0 | -100.0% |
| Q4 FY2025 | Dec 31, 2025 | $0 | -100.0% |
| Q3 FY2025 | Sep 30, 2025 | $0 | -100.0% |
| Q2 FY2025 | Jun 30, 2025 | $852.28K | +183.5% |
| Q1 FY2025 | Mar 31, 2025 | $1.64M | – |
| Q4 FY2024 | Dec 31, 2024 | $864.42K | – |
| Q3 FY2024 | Sep 30, 2024 | $2.79M | – |
| Q2 FY2024 | Jun 30, 2024 | $300.68K | – |
| Q1 FY2024 | Mar 31, 2024 | $0 | – |
| Q4 FY2023 | Dec 31, 2023 | $0 | – |
| Q3 FY2023 | Sep 30, 2023 | $0 | – |
| Q2 FY2023 | Jun 30, 2023 | $0 | – |
| Q1 FY2023 | Mar 31, 2023 | $0 | -100.0% |
| Q4 FY2022 | Dec 31, 2022 | $0 | -100.0% |
| Q3 FY2022 | Sep 30, 2022 | $0 | -100.0% |
| Q2 FY2022 | Jun 30, 2022 | $0 | -100.0% |
| Q1 FY2022 | Mar 31, 2022 | $81.53K | -26.2% |
| Q4 FY2021 | Dec 31, 2021 | $164.96K | -34.4% |
| Q3 FY2021 | Sep 30, 2021 | $30.41K | -92.7% |
| Q2 FY2021 | Jun 30, 2021 | $79.71K | -81.9% |
| Q1 FY2021 | Mar 31, 2021 | $110.42K | -84.6% |
| Q4 FY2020 | Dec 31, 2020 | $251.62K | -6.3% |
| Q3 FY2020 | Sep 30, 2020 | $415.46K | +24.7% |
| Q2 FY2020 | Jun 30, 2020 | $440.60K | +109.9% |
| Q1 FY2020 | Mar 31, 2020 | $715.98K | +96.6% |
| Q4 FY2019 | Dec 31, 2019 | $268.51K | -10.3% |
| Q3 FY2019 | Sep 30, 2019 | $333.21K | -4.6% |
| Q2 FY2019 | Jun 30, 2019 | $209.94K | +125.1% |
| Q1 FY2019 | Mar 31, 2019 | $364.23K | +64.6% |
| Q4 FY2018 | Dec 31, 2018 | $299.30K | +66.8% |
| Q3 FY2018 | Sep 30, 2018 | $349.34K | +40.9% |
| Q2 FY2018 | Jun 30, 2018 | $93.27K | -73.5% |
| Q1 FY2018 | Mar 31, 2018 | $221.30K | -25.2% |
| Q4 FY2017 | Dec 31, 2017 | $179.40K | – |
| Q3 FY2017 | Sep 30, 2017 | $247.99K | – |
| Q2 FY2017 | Jun 30, 2017 | $352.14K | – |
| Q1 FY2017 | Mar 31, 2017 | $295.74K | – |
See a number that looks wrong?